MannKind FY 2023 revenue doubled to $199M; Q4 posts GAAP net income of $1M

MANNKIND CORP

2023-FY EPS reported -$0.04 revenue$198,962,000

FY 2023 total revenues $199M, +99% YoY; Q4 revenues $58M, +62% YoY.
Q4 2023 net income of $1M (GAAP); Non-GAAP net income of $7M.
Afrezza Q4 net revenue $15.5M (+29%); Tyvaso DPI royalties Q4 $21.0M (+132%).
Cash $302.3M at year-end; plans Phase 3 for MNKD-101 and Phase 1 for MNKD-201 in H1 2024.
Commercial product gross margin 70% in Q4 vs 77% prior year; lower due to cost timing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MANNKIND CORP reported the quarter and full year ended December 31, 2023 results: revenue Total revenues of $199M, net income 4Q 2023 Net income of $1M.

Period: the quarter and full year ended December 31, 2023
Revenue: Total revenues of $199M
Net income: 4Q 2023 Net income of $1M
Result: reported results

Exact text from the filing

REPORTS 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 2023 Total revenues of $199M; +99% vs. 2022 • 4Q 2023 Total revenues of $58M; +62% vs. 2022 • 4Q 2023 Net income of $1M; Non-GAAP net income of $7M • $302M of cash and cash equivalents and investments at

View on SEC.gov

Browse all earnings releases →

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0000950170-24-021095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.